Serum HBV DNA suppression and seroconversion following long-term adefovir dipivoxil therapy in chronic hepatitis B patients.

被引：0
|
作者：
Heathcote, EJ
Jeffers, L
Perrillo, R
Wright, T
Sherman, M
Gilson, R
Shakil, AO
Namini, H
James, C
Ho, V
Fry, J
Brosgart, CL
机构：
[1] Toronto Western Hosp, Toronto, ON M5T 2S8, Canada
[2] Univ Miami, Miami, FL 33152 USA
[3] Ochsner Clin N 8, New Orleans, LA USA
[4] San Francisco VA Med Ctr, San Francisco, CA USA
[5] Toronto Gen Hosp, Toronto, ON, Canada
[6] Mortimer Market Ctr, London, England
[7] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[8] Gilead Sci Inc, Foster City, CA 94404 USA
来源：
HEPATOLOGY | 2001年 / 34卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
575
引用
收藏
页码：316A / 316A
页数：1
相关论文
共 50 条
  • [31] EFFECTIVENESS OF LONG-TERM COMBINATION THERAPY WITH ADEFOVIR DIPIVOXIL AND LAMIVUDINE IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B AND LAMIVUDINE RESISTANCE
    Manolakopoulos, Spilios
    Striki, Athanasia
    Papatheodoridis, George V.
    Deutsch, Melanie
    Mela, Maria
    Tzourmakliotis, Dimitrios
    Manesis, Emanuel K.
    Archimandritis, Athanasios J.
    HEPATOLOGY, 2009, 50 (04) : 520A - 521A
  • [32] Treatment of patients with chronic hepatitis B with adefovir dipivoxil
    Tong, MJ
    Tu, SS
    SEMINARS IN LIVER DISEASE, 2004, 24 : 37 - 44
  • [33] Resistance to adefovir dipivoxil in patients with chronic hepatitis B
    Nature Clinical Practice Gastroenterology & Hepatology, 2007, 4 (1): : 4 - 4
  • [34] Long-term experience of adefovir dipivoxil add-on therapy in chronic hepatitis B patients co-infected with HIV and lamivudine-resistant HBV: Absence of adefovir resistance mutation selection
    Thibault, V
    Benhamou, Y
    Brosgart, CL
    Xiong, S
    HEPATOLOGY, 2005, 42 (04) : 581A - 581A
  • [35] PROLONGED THERAPY WITH ADEFOVIR DIPIVOXIL IN CHILDREN WITH CHRONIC HEPATITIS B
    Jonas, Maureen M.
    Kelly, Deirdre A.
    Pollack, Henry
    Mizerski, Jacek
    Sorbel, Jeff
    Mondou, Elsa
    Sokal, Etienne M.
    HEPATOLOGY, 2011, 54 : 703A - 703A
  • [36] Frequency and risk factors of renal impairment during long-term adefovir dipivoxil treatment in chronic hepatitis B patients
    Kim, Yu Jin
    Cho, Hyun Chin
    Sinn, Dong Hyun
    Gwak, Geum-Youn
    Choi, Moon Seok
    Koh, Kwang Cheol
    Paik, Seung Woon
    Yoo, Byung Chul
    Lee, Joon Hyeok
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 (02) : 306 - 312
  • [37] Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil
    Yeon, J. E.
    Yoo, W.
    Hong, S. P.
    Chang, Y. J.
    Yu, S. K.
    Kim, J. H.
    Seo, Y. S.
    Chung, H. J.
    Moon, M. S.
    Kim, S-O
    Byun, K. S.
    Lee, C. H.
    GUT, 2006, 55 (10) : 1488 - 1495
  • [38] Durability of HBeAg seroconversion after adefovir dipivoxil treatment for chronic hepatitis B (CHB)
    Chang, TT
    Shiffman, M
    Tong, M
    Marcellin, P
    Liaw, YF
    Luengrojanakul, P
    Choy, GS
    James, C
    Ma, I
    Xiong, S
    Currie, G
    Brosgart, CL
    JOURNAL OF HEPATOLOGY, 2004, 40 : 126 - 126
  • [39] Long-term efficacy and safety of adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B (CHB) patients
    Marcellin, Patrick
    Chang, Ting-Tsung
    Lim, Seng Gee
    Sievert, William
    Tong, Myron
    Arterburn, Sarah
    Borroto-Esoda, Katyna
    Chuck, Steven
    HEPATOLOGY, 2006, 44 (04) : 548A - 548A
  • [40] Immune reconstitution after adefovir dipivoxil therapy in patients with chronic hepatitis B
    Jiang, Y. -F.
    Ma, Z. H. -H.
    Liu, Y. -Y.
    Wang, F.
    Xin, G. -J.
    Wang, B. -Y.
    Niu, J. -Q.
    JOURNAL OF HEPATOLOGY, 2008, 48 : S211 - S211
12345